ANEB News and Press, Anebulo Pharmaceuticals Inc. From 03/08/23

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions PR Newswire Additional operational efficiencies and opportunities expected with the engagement of Potrero Hill Advisors Sandra Gardiner succeeds Rex Merchant as acting chief financial officer ...

NEW YORK, NY / ACCESSWIRE / February 14, 2023 / Sidoti & Company, LLC announces that its two spring conferences are now open for registration. The March Virtual Small-Cap Conference will take place on Wednesday and Thursday, March 22-23, 2023, and the May Virtual Micro-Cap Conference wil...

Anebulo Pharmaceuticals press release ( NASDAQ: ANEB ): Q2 GAAP EPS of -$0.15 misses by $0.04 . Cash was $16.4 million as of December 31, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.15 misses by $0.04

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the th...

Summary Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not believe the market potential for "acute intoxication" to be as lucrative as the...

Preliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects Full PK, PD, and safety data expected by end of 1Q2023 Company targeting an End of Phase 2A meeting with FDA in the first half of 20...

Anebulo Pharmaceuticals press release ( NASDAQ: ANEB ): Q1 GAAP EPS of -$0.11 misses by $0.01 . Cash was $19.2 million as of September 30, 2022. For further details see: Anebulo Pharmaceuticals GAAP EPS of -$0.11 misses by $0.01

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial result...

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), today announced t...

Anebulo Pharmaceuticals ( NASDAQ: ANEB ) will sell an aggregate of 2.3M shares and accompanying warrants to purchase up to 2.3M shares to certain institutional accredited investors through a private investment in public equity financing at $2.935 per share and accompanyin...